0000899243-19-014964.txt : 20190528
0000899243-19-014964.hdr.sgml : 20190528
20190528211844
ACCESSION NUMBER: 0000899243-19-014964
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190523
FILED AS OF DATE: 20190528
DATE AS OF CHANGE: 20190528
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENRIGHT PATRICK G
CENTRAL INDEX KEY: 0001253886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 19859523
MAIL ADDRESS:
STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC
STREET 2: 800 EL CAMINO REAL, SUITE 220
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-23
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001253886
ENRIGHT PATRICK G
C/O LONGITUDE CAPITAL PARTNERS II, LLC
2740 SAND HILL ROAD, SECOND FLOOR
MENLO PARK
CA
94025
1
0
0
0
Common Stock, $0.0001 par value
2019-05-23
4
A
0
6442
0.00
A
33061
D
Common Stock, $0.0001 par value
6013134
I
By: LVP2
Stock Option (right to buy)
19.90
2019-05-23
4
A
0
11432
0.00
A
2029-05-23
Common Stock
11432
11432
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. Patrick G. Enright is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Patrick G. Enright
2019-05-28